

Glaucoma Market to witness growth by 2034, estimates DelveInsight | Allergan, Santen Pharmaceutical, Kowa Ltd., Alcon

Glaucoma companies are Allergan, Santen Pharmaceutical, Kowa, Senju Pharmaceuticals, Otsuka Pharmaceuticals, Bausch & Lomb, Ono Pharmaceutical, Novartis, Merck.

ALBANY, NEW YORK, UNITED STATES, April 4, 2024 /EINPresswire.com/ -- DelveInsight's "Glaucoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Glaucoma, historical and forecasted epidemiology

as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Glaucoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Glaucoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Glaucoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Glaucoma market.

Request for a Free Sample Report @ [Glaucoma Market Forecast](#)

Some facts of the Glaucoma Market Report are:

- According to DelveInsight, Glaucoma market size is expected to grow at a decent CAGR by 2034.
- The total Glaucoma Market Size in the 7MM was around USD 4,073 million in 2022.
- Leading Glaucoma companies working in the market are Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Ophthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.



- Key Glaucoma Therapies expected to launch in the market are ROCKLATAN/ ROCLANDA, DURYSTA (bimatoprost SR), NCX-470, TRS01, iDose TR (travoprost intraocular implant), and others.
- On February 2024, Laboratoires Thea announced a study for Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
- On March 2024, Amneal Pharmaceuticals announced a Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes.

Glaucoma Overview

Glaucoma is a group of eye conditions characterized by damage to the optic nerve, often linked to elevated intraocular pressure (IOP). It is a leading cause of irreversible blindness worldwide. Glaucoma typically progresses slowly, often without noticeable symptoms until significant vision loss occurs. The two main types are open-angle glaucoma, where drainage of fluid within the eye becomes less efficient over time, and angle-closure glaucoma, caused by a sudden blockage of fluid drainage. Risk factors include age, family history, ethnicity, and certain medical conditions. Treatment aims to lower IOP through medications, laser therapy, or surgery to prevent further vision loss. Regular eye exams are crucial for early detection and management. Research continues to explore new treatments and approaches to better understand and manage this sight-threatening condition.

Learn more about Glaucoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/glaucoma-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Glaucoma Market

The Glaucoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Glaucoma market trends by analysing the impact of current Glaucoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Glaucoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Glaucoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Glaucoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Glaucoma Epidemiology

The Glaucoma epidemiology section provides insights into the historical and current Glaucoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Glaucoma market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Glaucoma Epidemiology @ [Glaucoma Market Dynamics and Trends](#)

Glaucoma Drugs Uptake

This section focuses on the uptake rate of the potential Glaucoma drugs recently launched in the Glaucoma market or expected to be launched in 2020-2034. The analysis covers the Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Glaucoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Glaucoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Glaucoma Pipeline Development Activities

The Glaucoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Glaucoma key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Glaucoma pipeline development activities @ [Glaucoma Therapies and Drugs](#)

Glaucoma Therapeutics Assessment

Major key companies are working proactively in the Glaucoma Therapeutics market to develop novel therapies which will drive the Glaucoma treatment markets in the upcoming years are Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Ophthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.

Glaucoma Report Key Insights

1. Glaucoma Patient Population
2. Glaucoma Market Size and Trends
3. Key Cross Competition in the Glaucoma Market
4. Glaucoma Market Dynamics (Key Drivers and Barriers)
5. Glaucoma Market Opportunities
6. Glaucoma Therapeutic Approaches
7. Glaucoma Pipeline Analysis

8. Glaucoma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Glaucoma Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Glaucoma Competitive Intelligence Analysis
4. Glaucoma Market Overview at a Glance
5. Glaucoma Disease Background and Overview
6. Glaucoma Patient Journey
7. Glaucoma Epidemiology and Patient Population
8. Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Glaucoma Unmet Needs
10. Key Endpoints of Glaucoma Treatment
11. Glaucoma Marketed Products
12. Glaucoma Emerging Therapies
13. Glaucoma Seven Major Market Analysis
14. Attribute Analysis
15. Glaucoma Market Outlook (7 major markets)
16. Glaucoma Access and Reimbursement Overview
17. KOL Views on the Glaucoma Market
18. Glaucoma Market Drivers
19. Glaucoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/701056139>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.